1020 ET - Tuesday's 27% selloff in Sarepta Therapeutics after the death of a patient who received its Elevidys gene therapy makes for a compelling buying opportunity, according to Mizuho. In a note, Mizuho's Uy Ear says Sarepta's current stock price captures little value for Elevidys, as the value of Sarepta's exon-skipping for Duchenne Muscular Dystrophy and limb-girdle muscular dystrophy businesses add up to about $70 a share. Mizuho, with an outperform rating and $190 price target on Sarepta, says Sarepta management is standing by its 2025 guidance, and the analysts still see the Elevidys benefit/risk profile as positive. Sarepta up 6.3% to $78.09. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
March 19, 2025 10:20 ET (14:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.